Anti-inflammatory agents

Some ibuprofen users exceed daily NSAID dose limit

Research has shown that exceeding the daily dose limit for NSAIDs, which is linked to side effects such as increased risk of gastrointestinal bleeding, is not uncommon.…

No difference in cardiovascular risk of selective and non-selective NSAIDs, study finds

Most commonly used non-steroidal anti-inflammatory drugs (NSAIDs) have similar cardiovascular safety profiles, when given as a low-to-moderate daily dose for a short-term treatment period, a new study has concluded.…

Ibuprofen and paracetamol as effective for extremity pain as opioid combinations

Opioid use is the first-line treatment for severe acute extremity pain in emergency settings. However, research indicates that paracetamol may be equally effective.…

Scottish government continues to fund practitioner champions

The Scottish government has pledged to continue its £300,000 funding for community pharmacy practitioner champions this year.…

Pharmacological treatment options for fibromyalgia

Fibromyalgia is a high-impact and prevalent condition. Its clinical features include widespread pain and tenderness — often associated with high levels of poor-quality sleep, fatigue and cognitive dysfunction. The mechanism leading to fibromyalgia development is associated with a cha…

Ibuprofen raises blood pressure more than celecoxib

Study investigated the link between non-steroidal anti-inflammatory drugs and raised blood pressure and heart problems in patients who either had, or were at increased risk, of coronary artery disease. …

A brief history of ibuprofen

This timeline traces the history of popular anti-inflammatory drug ibuprofen, from its invention in the 1960s to its association with cardiac side effects.…

High-dose vitamin D counteracts sunburn damage

A double-blinded, placebo-controlled interventional trial reveals high-dose vitamin D3 as a potent modulator of experimental sunburn induced by simulated solar radiation.…

NSAIDs associated with significant improvement in chronic low back pain

Data from 13 clinical trials show efficacy of non-steroidal anti-inflammatory drugs in treating chronic low back pain.…

Ustekinumab approved by NICE for treatment of Crohn’s disease

The National Institute of Health and Care Excellence (NICE) has approved ustekinumab (Stelara; Janssen) as a treatment for patients with moderate to severe Crohn’s disease who have had little or no response, or an intolerance, to existing therapies.…